Intellikine secures funds for pipeline push
10 July 2009
Christopher Spillane
Please Login to read the full article.
10 July 2009
Christopher Spillane
christopher.spillane@informausa.com
Intellikine is to ramp up its clinical pipeline after investors committed up to $51 million into the company. The US firm will use the cash to push its phosphatidyinositol-3-kinase (PI3K) pathway inhibitors towards Phase I studies.
The isoform-selective inhibitors are in development for oncology,...
Please Login to read the full article.
RELATED CONTENT
FEATURES
- Merck BioVentures: where biosimilars make a difference
- DKSH highlights one-stop benefits as it builds Asia market expansion services
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
